Stock HNSA N HANSA BIOPHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Hansa Biopharma AB Mexican S.E.

Equities

HNSA N

SE0002148817

End-of-day quote Mexican S.E.
Other stock markets
 07:00:00 2023-03-15 pm EDT 		5-day change 1st Jan Change
160.8 MXN -.--% Intraday chart for Hansa Biopharma AB -.--% -.--%
May. 31 Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial MT
May. 31 Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial CI

Evolution of the average Target Price on Hansa Biopharma AB

Price target over the last 5 years

History of analyst recommendation changes

7b22b006fe39f6.7QvfBWiEeFN5kD07WmVcXz5Xnuu9FR10691r8EDqTJY.uHiUcwOzLn4B82xUCzcMck8l1p_fJSUgn-09uTasJOe0M5tyK7JAZjrofA~a63f5ca57f2d96eab33c5cf76f6dcf53

Analyst Recommendations on Hansa Biopharma AB

Hansa Biopharma's Follow-up Study Shows High Survival Rate for Imlifidase-enabled Kidney Transplant Patients MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
51.15 SEK
Average target price
105 SEK
Spread / Average Target
+105.28%
High Price Target
175 SEK
Spread / Highest target
+242.13%
Low Price Target
57 SEK
Spread / Lowest Target
+11.44%

Consensus detail

Consensus revision (last 18 months)

Ratings for Hansa Biopharma AB

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. HNSA Stock
  4. HNSA N Stock
  5. Consensus Hansa Biopharma AB